Search results
Showing 151 to 165 of 187 results for prostate cancer
High-intensity focused ultrasound for prostate cancer (IPG118)
We have moved interventional procedures guidance 118 to become HealthTech guidance 70. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)
We have moved Diagnostics guidance 53 to become HealthTech guidance 678. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Focal therapy using cryoablation for localised prostate cancer (IPG423)
Interventional procedures, IPG423 - Issued: April 2012 --> We have moved interventional procedures guidance 423 to become HealthTech guidance 284. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Low dose rate brachytherapy for localised prostate cancer (IPG132)
We have moved interventional procedures guidance 132 to become HealthTech guidance 81. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Discontinued Reference number: GID-TA10779
Faster, fairer access to HealthTech under new national programme
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)
We have moved interventional procedures guidance 756 to become HealthTech guidance 667. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG424)
Interventional procedures, IPG424 - Issued: April 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 667.
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
This guidance has been updated and replaced by NICE interventional procedures guidance 752.
We have moved interventional procedures guidance 752 to become HealthTech guidance 659. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)
This guidance has been updated and replaced by NICE technology appraisal guidance 412.
Discontinued Reference number: GID-TA11252